Written By Kami Davis 🌹🍃
Hi guys.. I hope everyone is having a fantastic summer!!! 🏄♀️🏖👙☀️
Just wanted to hop on and give thanks to the American Kratom Association and all the hard work they do.
Below is a collage of scientific studies on Kratom, published by the American Kratom Association. You can also find a list of reputable vendors that are all GMP certified on their website, at https://www.americankratom.org/vendor/gmp-participants.html
The American Kratom Association ~
June 16th, 2021
‘We often encourage elected officials to follow the science on kratom, but what are some of the most impactful scientific articles for us to read and share? To help answer that question we’ve compiled a top ten list that kratom advocates can read and share with family, friends, and our elected officials.’
‘Citation and online link:’
Obeng, S., Kamble, S. H., Reeves, M. E., Restrepo, L. F… & McCurdy, C. R. (2020). Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. Journal of medicinal chemistry, 63(1), 433–439.
Wilson, Harris, Eans, Brice-Tutt, …. and McCurdy, Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence, Drug and Alcohol Dependence, Volume 216, 2020.
Behnood-Rod A, Chellian R, Wilson R, Hiranita T, Sharma A, Leon F, McCurdy CR, McMahon LR, Bruijnzeel AW. Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug Alcohol Depend. 2020 Oct 1;215:108235.
Harun, N., Johari, I. S., Mansor, S. M., & Shoaib, M. Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats. Psychopharmacology, 237, 2020.
Hassan, R., Pike See, C., Sreenivasan, S., Mansor, S. M., Müller, C. P. & Hassan, Z. Mitragynine Attenuates Morphine Withdrawal Effects in Rats-A Comparison with Methadone and Buprenorphine. Frontiers in Psychiatry, 11, 2020.
Hemby, S.E., McIntosh, S., Leon, F., Cutler, S.J., & McCurdy, C.R., Abuse liability and therapeutic potential of the Mitragyna speciosa (Kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addiction Biology, 24, 2019.
Yue, K., Kopajtic, T.A. & Katz, J.L., Abuse liability of mitragynine assessed with a self-administration procedure in rats. Psychopharmacology (Berl), 235, 2018
Garcia-Romeu, A., Cox, D.J., Smith, K.E., Dunn, K.E. & Griffiths, R.R. Kratom: User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence, 2020
Henningfield, J.E., Fant, R.V., and Wang, D.W., The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology, 235, 2019.
Henningfield, J.E., Grundmann, O., Babin, J.K., Fant, R.V., Wang, D.W. & Cone, E.J., Risk of death associated with Kratom use compared to opioids. Preventive Medicine, 2019.
Grundmann, O. Patterns of Kratom use and health impact in the US—Results from an online survey. Drug and Alcohol Dependence, 176, 2017.
Kruegel, A.C. & Grundmann, O., The medicinal chemistry and neuropharmacology of Kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology, 134, 2018.
Prozialeck, W.C., Avery, B.A., Boyer, E.W., Grundmann, O., Henningfield, J.E., et al. Kratom policy: The challenge of balancing therapeutic potential with public safety. International Journal of Drug Policy, 2019.
Please donate at https://www.americankratom.org/
Written By Kami Davis 🌹🍃